TRVN - トレベナ (Trevena Inc.)

TRVNのニュース

   Livongo Health and Trevena among healthcare gainers; ObsEva among losers  2020/07/06 15:03:36 Seeking Alpha
Gainers: Trinity Biotech (NASDAQ:TRIB) +13%. Zynex (NASDAQ:ZYXI) +13%. Livongo Health (NASDAQ:LVGO) +12%. Trevena (NASDAQ:TRVN) +11%. Mesoblast MESO +11%.
   Thinking about buying stock in Trevena, Translate Bio, Workhorse Group, Dynavax Technologies, or Seelos Therapeutics?  2020/06/24 13:31:00 PR Newswire
NEW YORK, June 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRVN, TBIO, WKHS, DVAX, and SEEL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout  2020/06/23 11:57:59 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announced full exercise of over-allotment option in IPO) Cytokinetics, Inc. (NASDAQ: CYTK ) Dyadic International, Inc. (NASDAQ: DYAI ) Evoke Pharma Inc (NASDAQ: EVOK ) ( announced FDA approval for inhaled formulation of its gastroparesis drug) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (moved higher on an analyst upgrade) GENMAB A/S/S ADR (NASDAQ: GMAB ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Halozyme Therapeutics, Inc.
   The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs  2020/06/19 11:41:54 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Alpine Immune Sciences Inc (NASDAQ: ALPN )( announced a licensing agreement with AbbVie Inc (NYSE: ABBV ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Castle Biosciences Inc (NASDAQ: CSTL ) Cytokinetics, Inc. (NASDAQ: CYTK ) DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Neubase Therapeutics Inc (NASDAQ: NBSE ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Ovid Therapeutics Inc (NASDAQ: OVID ) Passage Bio Inc (NASDAQ: PASG ) Pliant Therapeutics Inc (NASDAQ: PLRX ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Royalty Pharma plc (NASDAQ: RPRX ) (IPOed Monday) Sarepta Therapeutics Inc (NASDAQ: SRPT )(announced a licensing agreement with Selecta Biosciences Inc (NASDAQ: SELB ) for licensing the latter's immune tolerance platform, ImmTOR for use in Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TELA Bio Inc (NASDAQ: TELA ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Trevena Inc (NASDAQ: TRVN ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 18) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Stocks In Focus Mylan Wins Patent Lawsuit Against Biogen With Respect To Multiple Sclerosis Drug Mylan NV (NASDAQ: MYL ) said the U.S.
   Thinking about buying stock in Tenax Therapeutics, Allena Pharmaceuticals, Trevena, Adaptimmune Therapeutics, or Aurora Cannabis?  2020/06/02 13:31:00 PR Newswire
NEW YORK, June 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TENX, ALNA, TRVN, ADAP, and ACB. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Has Trevena, Inc. (TRVN) Outpaced Other Medical Stocks This Year?  2020/05/06 15:30:10 Zacks Investment Research
Is (TRVN) Outperforming Other Medical Stocks This Year?
   Trevena EPS beats by $0.02  2020/03/12 11:03:58 Seeking Alpha
Trevena (NASDAQ:TRVN): Q4 GAAP EPS of -$0.07 beats by $0.02. Revenue of $0.03M (-87.0% Y/Y) Press Release
   Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance  2020/03/06 15:47:00 Zacks Investment Research
FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.
   Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium®  2020/02/24 21:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointment of Carrie Bourdow, chief executive officer of Trevena, Inc., and Jason Keyes, chief financial officer of Equillium, to the Company’s Board of Directors (the “Board”). In addition, Wendy L. Dixon, Ph.D., has resigned from her position as chairwoman of the Board and member of the Board.
   Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA  2020/02/11 08:22:00 Zacks Investment Research
Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.
   Trevena EPS beats by $0.02  2020/03/12 11:03:58 Seeking Alpha
Trevena (NASDAQ:TRVN): Q4 GAAP EPS of -$0.07 beats by $0.02. Revenue of $0.03M (-87.0% Y/Y) Press Release
   Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance  2020/03/06 15:47:00 Zacks Investment Research
FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.
   Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium®  2020/02/24 21:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointment of Carrie Bourdow, chief executive officer of Trevena, Inc., and Jason Keyes, chief financial officer of Equillium, to the Company’s Board of Directors (the “Board”). In addition, Wendy L. Dixon, Ph.D., has resigned from her position as chairwoman of the Board and member of the Board.
   Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA  2020/02/11 08:22:00 Zacks Investment Research
Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.
   Trevena Sees Hammer Chart Pattern: Time to Buy?  2019/09/04 11:41:11 Yahoo Finance
Trevena has been struggling lately, but the selling pressure may be coming to an end soon.

calendar